New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial

(2019) Martin Reck et al.   Lancet Respiratory Medicine

The Role of Angiogenesis Inhibitors in the Era of Immune Checkpoint Inhibitors and Targeted Therapy in Metastatic Non-Small Cell Lung Cancer

(2019) Kirstin Perdrizet et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

A multicenter, open label, randomized phase III study of atezolizumab with platinum-pemetrexed and with or without bevacizumab for patients with advanced nonsquamous non-small cell lung cancer (WJOG11218L APPLE Study).

(2019) Yoshimasa Shiraishi et al.   JOURNAL OF CLINICAL ONCOLOGY

A multicenter, open label, randomized phase II study of osimertinib plus ramucirumab versus osimertinib alone as initial chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer: TORG1833.

(2019) Yoshiro Nakahara et al.   JOURNAL OF CLINICAL ONCOLOGY

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial

(2019) Haruhiro Saito et al.   LANCET ONCOLOGY

Pemetrexed, Bevacizumab, or the Combination As Maintenance Therapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer: ECOG-ACRIN 5508

(2019) Suresh S. Ramalingam et al.   JOURNAL OF CLINICAL ONCOLOGY

Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial

(2019) Roy S Herbst et al.   LANCET ONCOLOGY

1480OCTONG 1509: Phase III study of bevacizumab with or without erlotinib in untreated Chinese patients with advanced EGFR-mutated NSCLC

(2019) Q Zhou et al.   ANNALS OF ONCOLOGY

MA14.07 Phase I Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naïve Non-Small Cell Lung Cancer (JVDF)

(2019) R. Herbst et al.   Journal of Thoracic Oncology

Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)

(2018) Baohui Han et al.   BRITISH JOURNAL OF CANCER

Treatment rationale and design of the SPIRAL study

(2018) Junji Uchino et al.   MEDICINE

Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges

(2018) Dai Fukumura et al.   Nature Reviews Clinical Oncology

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

(2018) Mark A. Socinski et al.   NEW ENGLAND JOURNAL OF MEDICINE

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations: NEJ026.

(2018) Naoki Furuya et al.   JOURNAL OF CLINICAL ONCOLOGY

Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive non-squamous non–small-cell lung cancer (NSCLC): Survival follow-up results of JO25567.

(2018) Noboru Yamamoto et al.   JOURNAL OF CLINICAL ONCOLOGY

Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC.

(2018) Mark A. Socinski et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non–Small Cell Lung Cancer

(2018) Cesare Gridelli et al.   JAMA Oncology

Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer

(2018) Baohui Han et al.   JAMA Oncology

Phase 2 Study of Afatinib Alone or Combined With Bevacizumab in Chemonaive Patients With Advanced Non–Small-Cell Lung Cancer Harboring EGFR Mutations: AfaBev-CS Study Protocol

(2018) Takashi Ninomiya et al.   Clinical Lung Cancer

Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for non-small cell lung cancer therapy

(2018) Jun Lu et al.   EUROPEAN RESPIRATORY JOURNAL

Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model

(2017) Chinami Masuda et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

P3.01-070 A Phase II Study of Fruquintinib in Combination with Gefitinib in Stage IIIb/IV NSCLC Patients Harboring EGFR Activating Mutations

(2017) S. Lu et al.   Journal of Thoracic Oncology

Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study—CALGB 30607 (Alliance)

(2017) Maria Q. Baggstrom et al.   Journal of Thoracic Oncology

The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC

(2017) Christian Manegold et al.   Journal of Thoracic Oncology

Loss of HIF-1α in natural killer cells inhibits tumour growth by stimulating non-productive angiogenesis

(2017) Ewelina Krzywinska et al.   Nature Communications

Strategies targeting angiogenesis in advanced non-small cell lung cancer

(2017) Jun Wang et al.   Oncotarget

A randomized phase II study of pemetrexed (PEM) with or without sorafenib (S) as second-line therapy in advanced non-small cell lung cancer (NSCLC) of nonsquamous histology: NCCTG N0626 study.

(2017) J. R. Molina et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer treatment and survivorship statistics, 2016

(2016) Kimberly D. Miller et al.   CA-A CANCER JOURNAL FOR CLINICIANS

VEGF-A Expression Correlates with TP53 Mutations in Non-Small Cell Lung Cancer: Implications for Antiangiogenesis Therapy

(2015) M. Schwaederle et al.   CANCER RESEARCH

BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non–Small-Cell Lung Cancer

(2015) Caicun Zhou et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Gefitinib in Combination with Bevacizumab as First-Line Therapy for Advanced Non–Small Cell Lung Cancer with Activating EGFR Gene Mutations: The Okayama Lung Cancer Study Group Trial 1001

(2015) Eiki Ichihara et al.   Journal of Thoracic Oncology

Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer

(2014) Robert C. Doebele et al.   CANCER

Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Maintenance as Monotherapy or in Combination With Bevacizumab (BEV) for Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Chemotherapy

(2014) N.A. Rizvi et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Biomarker Analyses from a Randomized, Placebo-Controlled, Phase IIIb Trial Comparing Bevacizumab with or without Erlotinib as Maintenance Therapy for the Treatment of Advanced Non-Small-Cell Lung Cancer (ATLAS)

(2014) Fairooz Kabbinavar et al.   Journal of Thoracic Oncology

A Correlative Biomarker Analysis of the Combination of Bevacizumab and Carboplatin-Based Chemotherapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer: Results of the Phase II Randomized ABIGAIL Study (BO21015)

(2014) Tony Mok et al.   Journal of Thoracic Oncology

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

(2014) Edward B Garon et al.   LANCET

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

(2014) Martin Reck et al.   LANCET ONCOLOGY

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

(2014) Takashi Seto et al.   LANCET ONCOLOGY

Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors

(2014) Gregory T Motz et al.   NATURE MEDICINE

Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effectin vivo

(2013) S. Yasuda et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

ATLAS: Randomized, Double-Blind, Placebo-Controlled, Phase IIIB Trial Comparing Bevacizumab Therapy With or Without Erlotinib, After Completion of Chemotherapy, With Bevacizumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

(2013) Bruce E. Johnson et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non–Small-Cell Lung Cancer: AVAPERL (MO22089)

(2013) Fabrice Barlesi et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab improves the antitumor efficacy of adoptive cytokine-induced killer cells therapy in non-small cell lung cancer models

(2013) Leilei Tao et al.   MEDICAL ONCOLOGY

VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer

(2012) M. Terme et al.   CANCER RESEARCH

Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Gemcitabine/Cisplatin Alone or With Sorafenib for the First-Line Treatment of Advanced, Nonsquamous Non–Small-Cell Lung Cancer

(2012) Luis G. Paz-Ares et al.   JOURNAL OF CLINICAL ONCOLOGY

Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer: A Phase III Trial

(2012) Giorgio V. Scagliotti et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non-squamous non-small cell lung cancer who have not received prior chemotherapy: A substudy of the Avastin in Lung trial

(2011) Tony SK MOK et al.   Asia-Pacific Journal of Clinical Oncology

YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo

(2011) Shu Tian et al.   CANCER SCIENCE

Vandetanib Plus Pemetrexed for the Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer: A Randomized, Double-Blind Phase III Trial

(2011) Richard H. de Boer et al.   JOURNAL OF CLINICAL ONCOLOGY

Predictive Value of Intratumoral Microvascular Density in Patients with Advanced Non-small Cell Lung Cancer Receiving Chemotherapy Plus Bevacizumab

(2011) Yuan-Yuan Zhao et al.   Journal of Thoracic Oncology

Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial

(2011) Roy S Herbst et al.   LANCET

Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

(2010) M. Reck et al.   ANNALS OF ONCOLOGY

Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non–Small-Cell Lung Cancer

(2010) Giorgio Scagliotti et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL

(2009) Martin Reck et al.   JOURNAL OF CLINICAL ONCOLOGY

Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients

(2008) J. H. Finke et al.   CLINICAL CANCER RESEARCH